Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 66,300 shares, a drop of 96.4% from the December 31st total of 1,840,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.4% of the company’s stock are sold short.

Institutional Investors Weigh In On Palisade Bio

An institutional investor recently bought a new position in Palisade Bio stock. JPMorgan Chase & Co. acquired a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio as of its most recent filing with the Securities & Exchange Commission. 11.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on PALI. Maxim Group dropped their price target on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Brookline Capital Management initiated coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They issued a “buy” rating and a $38.00 price objective on the stock.

Palisade Bio Price Performance

Shares of Palisade Bio stock traded up $0.01 during midday trading on Tuesday, hitting $1.50. The company had a trading volume of 142,578 shares, compared to its average volume of 1,060,419. The business’s 50 day simple moving average is $1.90 and its two-hundred day simple moving average is $2.96. The stock has a market cap of $4.17 million, a PE ratio of -0.11 and a beta of 1.42. Palisade Bio has a 1-year low of $1.33 and a 1-year high of $22.35.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.35) by $1.03. On average, sell-side analysts expect that Palisade Bio will post -12.43 EPS for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.